GLYC - Treatment gets underway in early-stage leukemia trial of GlycoMimetics' uproleselan

GlycoMimetics (GLYC) announces that the first patient was treated in an early-stage study evaluating the company’s lead drug candidate, uproleselan, added to cladribine plus low dose cytarabine ((LDAC)) in patients with treated secondary acute myeloid leukemia ((ts-AML)).The investigator-sponsored trial is enrolling patients 18 years or older, with a diagnosis of ts-AML who have not received therapy for their AML.Clinicians plan to enroll about 25 patients in the trial.The study is designed to evaluate both the safety and tolerability of the combination therapy, as well as to identify a recommended Phase 2 dose of the uproleselan triple combination.Among the trial’s secondary objectives are efficacy assessments including overall response rate, complete response, complete response without blood count recovery, and other measures.Shares up more than 4% premarket.

For further details see:

Treatment gets underway in early-stage leukemia trial of GlycoMimetics' uproleselan